Figure 1.
Migration of administered hUCB-MSCs into the ischemic brain. (a) Representative hematoxylin and eosin staining of coronal sections from ischemic brain. (b) At 7 days and (c) 28 days after 1 × 106 hUCB-MSC administration, hUCB-MSCs were identified by the staining with human nuclei antibody (hNA, green) and the numbers of hNA-positive cells in the ischemic boundary zone (IBZ) of Ipsi hemisphere are illustrated (n = 4 per treatment group). (d) Data are presented as mean numbers of hNA-positive cells ± SD. Note that the numbers of hNA-positive cells were decreased in animals after intravenous administration compared with animals after intrathecal administration. Intrathecally treated groups showed significant differences from the intravenously treated groups in the IBZ (analysis of variance; *P < 0.05). Nuclei were counterstained with DAPI (blue). Scale bar = 20 μm.